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Abstract
Background: Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical
activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with
resectable colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), urothelial cell cancer (UCC), and renal cell cancer
(RCC) with a comparator intratumoral (IT) dosed CRC patient cohort.
Methods: Seventeen patients scheduled for primary tumor resection were enrolled. IT injection of enadenotucirev (CRC
only) was administered as a single dose (≤ 3 × 1011 viral particles [vp]) on day 1, followed by resection during days 8–15.
IV infusion of enadenotucirev was administered by three separate doses (1 × 1012 vp) on days 1, 3, and 5, followed by
resection during days 8–15 (CRC) or days 10–25 (NSCLC, UCC, and RCC). Enadenotucirev activity was measured using
immunohistochemical staining of nuclear viral hexon and quantitative polymerase chain reaction for viral genomic DNA.
Results: Delivery of enadenotucirev was observed in most tumor samples following IV infusion, with little or
no demonstrable activity in normal tissue. This virus delivery (by both IV and IT dosing) was accompanied by
high local CD8+ cell infiltration in 80% of tested tumor samples, suggesting a potential enadenotucirev-driven
immune response. Both methods of enadenotucirev delivery were well tolerated, with no treatment-associated
serious adverse events.
Conclusions: This study provides key delivery and feasibility data to support the use of IV infusion of enadenotucirev,
or therapeutic transgene-bearing derivatives of it, in clinical trials across a range of epithelial tumors, including the
ongoing combination study of enadenotucirev with the checkpoint inhibitor nivolumab. It also provides insights into
the potential immune-stimulating properties of enadenotucirev.
Trial registration: This MOA study was a phase 1, multicenter, non-randomized, open-label study to investigate the
administration of enadenotucirev in a preoperative setting (ClinicalTrials.gov: NCT02053220).
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Oncolytic viruses hold great promise for the effective treat-
ment of cancer because of their unique cell-killing mecha-
nisms, tumor-selective replication, amplification of the
initial therapy dose through replication in vivo, and poten-
tial to provoke an anticancer immune response [1, 2]. Al-
though a variety of genetically modified viruses have been
developed as oncolytic agents [1, 3, 4], our incomplete un-
derstanding of both tumor and virus biology can limit opti-
mal design of oncolytic viruses [5, 6]. Therefore, a more
effective approach may be to avoid rational design of vi-
ruses altogether in favor of directed evolution (i.e. genetic
diversification followed by phenotypic selection) [5, 6].
Enadenotucirev (formerly known as ColoAd1), a novel
group B Ad11p/Ad3 chimeric adenovirus, is the first onco-
lytic virus to be successfully developed using this approach
[7]. Enadenotucirev is more potent than its parental strains
and other wild-type or genetically engineered adenoviruses
that it has been compared with to date, and, in terms of
both virus replication and killing of tumor cell lines and
primary tissues, has demonstrated greater tumor selectiv-
ity, particularly against epithelial carcinomas [7–12].
The primary oncolytic action of enadenotucirev is
through a direct non-apoptotic, pro-inflammatory cell-
killing mechanism, similar to oncosis or ischemic cell
death [10]. As non-apoptotic lytic pathways of cell death
can be highly immunogenic [13], oncolytic viruses may
also create a pro-inflammatory environment and stimulate
an anticancer immune response [14]. In addition, a recent
study has shown that enadenotucirev directly participates
in innate immune activation via the CD46 receptor on
dendritic cells [15].
Systemic delivery through intravenous (IV) infusion is
a major goal in the delivery of oncolytic viruses, so that
the agent is able to access both the primary tumor and
metastatic lesions [1, 16]. To date, talimogene laherpar-
epvec (an attenuated herpes simplex virus type-1 pro-
duced in Vero cells by recombinant DNA technology) is
the only oncolytic virus therapy to be licensed by the
European Medicines Agency and the US Food and Drug
Administration – for the local treatment of unresectable
melanoma [3, 4, 17]. However, talimogene laherparepvec
is delivered by intratumoral (IT) injection, restricting its
use to accessible tumors and requiring specialist skills,
particularly for non-superficial tumors.
Historically, many studies have failed to demonstrate
appreciable antitumor activity when oncolytic viruses
are delivered via IV infusion [18, 19], probably stemming
from a combination of neutralizing antibodies, antiviral
cytokine response, complement-mediated inactivation,
uptake by Kupffer cells, and erythrocyte sequestration
[14, 20–22]. Novel design strategies, such as antigenic
masking [23] and immunosuppression [24], are being
explored as strategies to resolve these difficulties.
Enadenotucirev was prioritized for clinical develop-
ment and delivery by IV infusion on the basis of preclin-
ical evidence of its stability in human whole blood [25]
and the low prevalence of neutralizing antibodies against
group B adenoviruses (including Ad11p, the exclusive
component of the outer coat of enadenotucirev) in the
general population [26, 27].
This phase 1 Mechanism Of Action (MOA) study was
conducted to assess the pattern of viral delivery and viral
expression, anti-tumor immune response, and safety of
enadenotucirev delivered by IV infusion or IT injection
in patients with colorectal cancer (CRC) and other epi-
thelial tumors. The data demonstrate that enadenotu-
cirev can access and replicate within tumor tissue, with
successful delivery regardless of the route of administra-
tion. The data also provide some evidence supporting
the stimulation of an induced immune response by ena-
denotucirev. Both modes of delivery are shown to be
feasible and well tolerated.
Methods
Study design and treatment regimens
The study was initially planned in two cohorts of patients
with CRC, to investigate the route of enadenotucirev ad-
ministration: IT injection (cohort A) and IV infusion (co-
hort B; Fig. 1). It was then extended to investigate IV
infusion of enadenotucirev in patients with non-small-cell
lung cancer (NSCLC, cohort C), urothelial cell cancer
(UCC, cohort D), and renal cell cancer (RCC, cohort E).
The main eligibility criteria included age 18 years or older,
and histologically confirmed early stage CRC, NSCLC,
UCC, or RCC, and a primary tumor diameter of at least
3 cm, scheduled for tumor resection. For patients with
CRC in cohort A, the tumor had to be accessible by col-
onoscopy in order to allow IT injection of enadenotucirev.
Patients were not eligible if they had rectal tumors or ob-
structive tumors of the intestine or urinary tract, another
primary malignancy (except for non-melanoma skin can-
cer or cervical cancer in situ) in the previous 3 years,
known central nervous system metastases, or any known
condition necessitating tumor resection within 8–10 days
of enadenotucirev administration. The treatment period
comprised a single cycle of treatment, surgery, and follow-
up visits, lasting 22 days in patients with CRC and 33 days
in patients with other tumor types. The end-of-study visit
was 55 days after the last administration of enadenotu-
cirev, or 28 days after surgery, whichever occurred later.
Patients with CRC in cohort A received a single IT in-
jection of enadenotucirev at the time of presurgical colon-
oscopy (study day 1). A variable volume of the diluted
virus (1 × 1011 viral particles [vp]/mL) was administered
using repeated needle insertions; the dose was based on
the available surface area of the tumor, up to a planned
maximum dose of 8 × 1011 vp (8 mL); the actual doses




















administered were 0.6–3.0 × 1011 vp. This was followed
by laparoscopic or open surgery during days 8–15. The
dose for the IT injection was determined from preclinical
data, aiming to achieve measurable transgene expression
while minimizing any spill - over into the bloodstream.
Patients with CRC in cohort B received three separate
IV infusions of diluted virus (1 × 1012 vp) on days 1, 3,
and 5, each given over 5 min, followed by laparoscopic
or open surgery during days 8–15. Patients with NSCLC,
UCC, or RCC (cohorts C–E) also received three separate
doses of diluted virus (1 × 1012 vp) by IV infusion on
days 1, 3, and 5, but followed by laparoscopic or open
surgery during days 10–25 (in one patient, surgery was
delayed until day 52 due to surgeon decision). The dose
of enadenotucirev for IV infusion was determined to be
safe and tolerable from early data of the preliminary
phase 1 Evolve study (NCT02028442; manuscript in
preparation).
Histopathology and immunohistochemistry
The tissue samples obtained during surgery were staged
by the local pathologist and then prepared for specific
analyses. Up to three tumor blocks, one visually normal
tissue block from the tumor margin, and one draining
lymph node block (when available) were fixed in 10% neu-
tral buffered formalin or 4% neutral buffered formalde-
hyde for 18–24 h and then embedded in paraffin. Some
larger tissue blocks were further fragmented into 2–4
pieces each and re-embedded to aid sectioning and to en-
able evaluation of more regions of the tumor. A set of 21
sections was prepared from each tissue block for histo-
pathologic assessment by a GCP-compliant laboratory
(Targos Molecular Pathology GmbH, Kassel, Germany), in
order to determine the extent of delivery and spread of
enadenotucirev, and to detect any evidence of an immune
response. If sufficient tumor had been resected and the
patient had provided separate consent, additional tissue
samples were frozen at −20 °C for exploratory analyses
(detection of viral DNA using quantitative polymerase
chain reaction [qPCR]).
Immunohistochemistry (IHC) was performed on sections
6, 9, 12, 15, 18, and 21 to detect enadenotucirev hexon –
the major adenovirus capsid protein. Hexon protein is
expressed late during infection, only after viral genome rep-
lication has occurred, and is transported to the nucleus for
final virus assembly, where it usually forms honeycomb-like
intranuclear inclusion bodies. Nuclear detection of inclu-
sion bodies in tumor tissue block sections therefore indi-
cates that the virus has undergone all the major steps of
replication. The staining procedure used a pan-hexon
monoclonal antibody (1E11, Abcam, Cambridge, UK) and
was validated according to the ICH Q2 (R1) guidelines.
Staining was detected using aVentana UltraView Detection
Kit (Ventana Medical Systems Inc., Tucson, AZ, USA).
Fig. 1 Study design and patient disposition. a Two patients were excluded at screening because of inadequate renal function, and one because
of bowel obstruction. b Cohorts C–E initiated after completion of cohort A and B comparison phase. c Enadenotucirev (EnAd) administration days
also counted as assessment visits (i.e. cohort A: day 1; cohort B: days 1, 3, and 5)




















Staining of enadenotucirev in each section was assessed by
a board-certified pathologist and the proportion of tumor
cells with positive staining (0–100%) determined.
Sections 1 and 2 were initially stained for enadenotu-
cirev hexon protein or an immunoglobulin G (IgG)
isotype control antibody, section 3 was used for
hematoxylin and eosin staining for histopathologic sub-
type assessment, and the remaining sections were used
for other inflammatory and virus receptor stains, in-
cluding cluster of differentiation (CD) 8, CD46, CD11b,
CD25, CD57, and desmoglein 2 (DSG2). Blocks were
also stained for the DNA mismatch repair proteins
MLH1 and MSH2. From the majority of patients with
CRC, further sections were subsequently prepared from
two or three blocks of resected tumor tissues and
stained for the immune markers CD4, forkhead box P3
(FoxP3), and programmed cell death 1 (PD-1) at Path-
ology Diagnostics Ltd. (Cambridge, UK). Scoring of
CD8 cell infiltration into tumor cell nests (as opposed
to tumor stroma) was assessed according to the method
of Naito et al. [28]. For each available stained section
scanned image, a 1 mm2 area with the most abundant
distribution of CD8 cells was selected, the number of
CD8 cells located within tumor cell nests was counted
by two independent scientists, using ImageJ software,
and the average of the two counts was taken for assess-
ment of the degree of CD8 infiltration according to the
following scoring criteria: 0 = No CD8 cells; 1–
19 = Low; 20–49 = Moderate; ≥ 50 = High.
Measurement of enadenotucirev in blood by qPCR
The concentration of enadenotucirev in blood was mea-
sured using qPCR to assess the pharmacokinetics of ena-
denotucirev immediately following IT injection and to
confirm virus concentrations following IV infusion. A
validated qPCR assay was used in a GCP-compliant la-
boratory (BioOutsource Ltd., Glasgow, UK). The qPCR
primers used were:
1. forward primer: ATCRCATGTCTAGACTTCGACR
CCAG
2. reverse primer: TGCTGGGTGATAACTATGGGGT
3. probe: 6 FAM-
ATCTGTGGAGTTCATCGCTCTCTTACG-
3 TAMRA.
4. The qPCR product is 2859 base pairs across the E2B
region of enadenotucirev.
Whole-blood samples were frozen immediately after
collection and stored at –20 °C until analysis. Blood
samples were spiked with bovine adenovirus to act as a
DNA extraction control; if bovine adenovirus recovery
was less than 50%, the sample extraction was repeated.
Each sample was tested in triplicate and the mean for
each sample calculated.
Detection of enadenotucirev in tumor samples by qPCR
Exploratory qPCR was used to detect enadenotucirev
genomic DNA, in order to support the IHC hexon stain-
ing data. Samples were semi-thawed and then cut into
small pieces using a sterile scalpel; each piece was then
weighed, fully lysed, and the DNA extracted. Samples
were analyzed by qPCR, as described above for detecting
the concentration of enadenotucirev in blood.
Viral shedding detected by qPCR (IT injection only)
Measurements of enadenotucirev shedding were per-
formed for cohort A only. Urine samples were obtained
by clean-catch urine collection, saliva samples were col-
lected using buccal swabs, and fecal samples were col-
lected using rectal swabs. These samples were collected
before IT injection of enadenotucirev and then on days
1, 2, 4, 8, 15, and 22, and at the end-of-study visit. The
samples were analyzed by qPCR, as described above.
Antibody response
For cohort A, serum was sampled before and after IT in-
jection of enadenotucirev on day 1, on days 8, 15, and
22, and at the end-of-study visit. For cohorts B–E, serum
was sampled before and after IV infusion on day 1, on
day 22 (cohort B) or before surgery on the day of surgery
(cohorts C–E), and at the end-of-study visit.
Serum samples (prediluted 1:100 to avoid serum inhib-
ition) were analyzed using an enzyme-linked immuno-
sorbent assay with electrochemiluminescence detection
(Meso Scale Diagnostics, Rockville, MD, USA). Briefly,
assay plates were coated with enadenotucirev for 1 h at a
concentration of 3.6 × 1010 vp/mL. After washing the
plates, serially titrated patient serum samples were added
and incubated for 1 h, followed by washing and addition
of the biotinylated anti-human IgG Fc detection antibody
(BioLegend, Cat. No. 409308) at 1 μg/mL. This detection
antibody cross-reacts with rabbit IgG, allowing the use of
a rabbit anti-enadenotucirev antiserum as a positive con-
trol in the assays. After an hour, plates were washed and
sulfo-tag labelled streptavidin (0.2 μg/mL) added for a fur-
ther hour and then processed for signal detection with an
MSD plate reader. Data were expressed as the reciprocal
dilution generating a statistically determined positive sig-
nal above background. Titers below 1/11 dilution were
considered as negative.
Cytokine response (IV infusion only)
Concentrations of interleukin (IL)-2, IL-4, IL-6, IL-10,
IL-12, interferon (IFN)γ, monocyte chemoattractant pro-
tein (MCP)-1, and tumor necrosis factor (TNF) in serum
were assessed for cohorts B–E (i.e. after IV infusion).




















Serum samples were collected before IV infusion of ena-
denotucirev, 6–8 h after infusion on days 1, 3 and 5, and
before surgery on the day of surgery. Serum samples
were analyzed using a Luminex bead-based multiplex
assay (R&D Systems, Abingdon, UK) by ACM Global
Laboratories (York, UK).
Safety assessments
A complete medical history was taken and a physical
examination performed at screening. Limited symptom-
directed physical examinations were performed at all
subsequent visits. Safety assessments were conducted at
each study visit. These included recording of adverse
events (AEs), from the time of informed consent until
the end-of-study visit, and laboratory safety tests
(hematology, coagulation profile, chemistry, and urinaly-
sis). Vital signs (systolic and diastolic blood pressure,
heart rate, oral temperature, and respiratory rate), East-
ern Cooperative Oncology Group performance status
[29], body weight, and height (for calculation of body
mass index) were also recorded.
Results
Patient population
Twenty patients were screened for study eligibility (Fig. 1),
of whom 17 were enrolled in the study and received treat-
ment. None of the patients had received any tumor-
related treatment before enrolment. Patients received
study treatment between 1 October 2013 and 6 February
2015. Sixteen patients completed study treatment; one pa-
tient (in cohort E) discontinued study treatment because
of a stoma site infection before the day 5 IV infusion of
enadenotucirev. All 17 patients who received at least one
dose of enadenotucirev underwent surgical resection of
their primary tumor and safety evaluations, and all
attended the end-of-study visit.
Ten patients with CRC entered the first stage of the
study; five were treated with enadenotucirev adminis-
tered by IT injection (cohort A) and five with enadeno-
tucirev administered by IV infusion (cohort B). Seven
additional patients, two with NSCLC (cohort C), two
with UCC (cohort D), and three with RCC (cohort E),
entered the second stage of the study and received ena-
denotucirev administered by IV infusion.
There were no notable differences in baseline char-
acteristics between cohorts A and B (Additional file 2:
Table S1).
Feasibility and safety profile
Administration of enadenotucirev by IT injection and IV
infusion was feasible and generally well tolerated (Table 1).
Exposure to enadenotucirev was lower with IT injection
(single administration of 0.6–3 × 1011 vp) than with IV in-
fusion (1 × 1012 vp administered over 5 min on days 1, 3,
and 5 in 11 patients, and on days 1 and 3 in one patient
[the day 5 dose was missed]), reflecting the direct adminis-
tration into the tumor.
All patients had at least one AE (any grade), and overall,
more AEs were reported following IV infusion than after IT
injection. Anemia was the only event reported in more than
one patient following IT injection but was not considered to
be related to treatment. Treatment-related AEs were re-
ported by 83.3% of patients following IV infusion; all were
considered mild or moderate in severity (grade 1 or 2). The
most commonly reported treatment-related AEs following
IV infusion were asthenia (33.3% of patients), neutropenia,
chills, and pyrexia (each 25.0% of patients). There were no
treatment-related deaths, treatment-related serious AEs
(SAEs), or treatment-related AEs that led to discontinuation.
No treatment-related AEs were reported following IT injec-
tion. Grade 3 laboratory abnormalities were reported in
three patients after administration of enadenotucirev; one of
these, low potassium on day 15 after IT administration of
enadenotucirev, was considered to be of clinical significance.
Enadenotucirev hexon staining
IHC assessments for enadenotucirev were performed on
446 samples, including tumor material and normal tissue
from the 10 patients with CRC. Lymph nodes, inflam-
matory tissue, and tubular adenoma were also available
for analysis from some patients. Clear evidence of enade-
notucirev in the tumors (punctate brown staining of
virus hexon protein in the nuclei) was found in all tumor
samples; examples are provided in Fig. 2. Within these
tumor sections, nuclear staining was observed in the
epithelially derived tumor cells, whereas cells in the
stroma and visually normal colon epithelial tissues gen-
erally did not stain (see Additional file 2: Table S2 and
Additional file 1: Figure S1 for more details of non-
tumor staining). Resection was delayed to day 52 in one
patient (IV0201); enadenotucirev was still detectable in
the tumor sample from this patient. Since the adenovirus
hexon protein is dependent on the virus major late pro-
moter, and is only produced subsequent to viral DNA
synthesis [30], the staining data also provided evidence
that virus replication had also initiated by the time sam-
ples were taken.
The distribution of enadenotucirev nuclear staining
through the tumor sections is summarized in Table 2.
After IV infusion, positive tumor cell staining was ob-
served in all 224 sections stained and in the majority of
sections (125 of 147) stained after IT injection. This dif-
ference is likely to be due to the focal deposition of the
virus following IT injection.
Immune-cell infiltration in tumors
Eight of the 10 samples from patients with CRC showed
high levels of CD8+ cell infiltration within the tumor cell




















nests (Table 3) and in the stromal tissue (representative
images are shown in Fig. 3). Tumor samples IT0203 and
IV0201 showed only low levels of tumor-associated CD8
+ cells. No suitable baseline tumor biopsy material was
available for analysis in parallel with the post-dose sec-
tions from these patients.
Although a direct comparison of CD8 cell numbers in
tumor tissues before and after treatment was not possible,
CD8+ T cells are generally considered to be rare in CRC tu-
mors and, if seen at higher levels, are usually associated
with a high level of microsatellite instability (MSI) [31].
However, none of the tumor samples were considered to
have high levels of MSI (i.e. MLH1 and MSH2 expression
was normal in all tumor blocks analyzed; Additional file 2:
Table S3). Therefore one hypothesis for the presence of
CD8+ cells would be that their entry was part of a
localized immune response, potentially driven by ena-
denotucirev virus infection within the tumor. Using
higher magnification, many of the CD8+ cells that infil-
trated the tumor cell nests appeared to have a pleomorphic
phenotype. The loss of a rounded phenotype is a hallmark
of T-cell activation and provides further observational
evidence for CD8+ T-cell activation [32].
To explore the nature of the immune cell infiltrates fur-
ther, another immunostaining was carried out. PD-1 is a
known co-marker with CD8 for tumor-infiltrating acti-
vated cytotoxic T cells [33]. As with CD8 staining, PD-1+
cells were detected within the tumor cell nests and in the
stromal tissue (Additional file 1: Figure S2). By contrast,
both CD4 and FoxP3 staining were primarily restricted to
the stromal regions of tumor sections taken from patients
with CRC regardless of whether they received enadenotu-
cirev by IT injection or IV infusion (Additional file 1:
Figure S2). CD4+ T-cells expressing FoxP3 are indicative
of regulatory T cells (Tregs) which are thought to promote
tumor progression by suppressing antitumor immunity in
Table 1 Adverse events in the safety population following IT injection or IV infusion
CRC (IT injection, n = 5) CRC, NSCLC, UCC, RCC (IV infusion, n = 12)
Any AE, n (%)a 5 (100.0) 12 (100.0)b





Any SAE, n (%) 1 (20.0) 3 (25.0)
Abdominal abscess 1 0
Enteritis 0 1
Subcutaneous emphysema 0 1
Wound dehiscence 0 1
Treatment-related SAE 0 (0.0) 0 (0.0)
Any grade 3 or 4 AEs, n (%) 2 (40.0) 3 (25.0)









Wound dehiscence 0 1
Treatment-related grade 3 or 4 AEs, n (%) 0 (0.0) 0 (0.0)
AE leading to study discontinuation, n (%) 0 (0.0) 1 (8.3)
Stoma site infection 0 1
aThe most commonly reported AEs following IV infusion were pyrexia (58.3% of patients), asthenia (51.7% of patients), abdominal pain (33.3% of patients), and
neutropenia (33.3% of patients)
bSpecific AEs are listed by occurrence rather than number of patients reporting them (i.e. a patient can have more than one concomitant AE)




















Fig. 2 Nuclear staining of enadenotucirev in samples from selected CRC patients (IT injection versus IV infusion). 1. Image IT-204-B9-12 (top left),
tumor section from a patient with CRC treated with enadenotucirev given by IT injection (cohort A): strong brown nuclear hexon staining of
tumor cells is visible in the bottom part of the tissue section. 2. Image IT-204-B9-12 (top right), a different region of the same tumor section in
1: nuclear hexon staining of tumor cells is visible throughout this area of the tissue section. 3. Image IV-201-B10-9 (middle left), tumor section
from a patient with CRC treated with enadenotucirev given by IV infusion (cohort B) but whose resection was delayed until day 52: nuclear hexon
staining of tumor cells (but not stroma) is still visible in this tissue. 4. Image IV-101-B8-1 (middle right), non-tumor (presumed normal) section from
a patient with CRC treated with enadenotucirev given by IV infusion (cohort B): little or no nuclear hexon staining is visible throughout the tissue
section. 5. Image IV-302-B6-2 (bottom left), isotype staining control
Table 2 Nuclear staining of enadenotucirev in patients with CRC (IT injection vs IV infusion)
Cohort Patient Total number
of sections
Nuclear staining (%)
0 > 0 ≤ 20 > 20 ≤ 40 > 40 ≤ 60 > 60 ≤ 80 > 80 ≤ 100 No tumor
A (IT injection) IT0201 42 0 31 8 3 0 0 0
IT0203 14 0 0 0 2 11 1 0
IT0204 42 1 0 0 0 4 30 7
IT0301 21 7 14 0 0 0 0 0
IT0302 28 14 11 2 1 0 0 0
Total, n (%) 147 (100.0) 22 (15.0) 56 (38.1) 10 (6.8) 6 (4.1) 15 (10.2) 31 (21.1) 7 (4.8)
B (IV infusion) IV0101 49 0 38 8 3 0 0 0
IV0201a 21 0 0 3 0 11 7 0
IV0301 70 0 25 11 13 6 8 7
IV0302b 63 0 21 9 9 4 6 14
IV0303 21 0 11 7 3 0 0 0
Totalb, n (%) 224 (100.0) 0 (0.0) 95 (42.4) 38 (17.0) 28 (12.5) 21 (9.4) 21 (9.4) 21 (9.4)
aPatient did not have surgery until 51 days after the first IV infusion of enadenotucirev
bNumber corrected from data source




















the tumor microenvironment [32–34]. The compartmen-
tal co-localization of CD4+ and FoxP3+ cells suggests that
a significant subset of the CD4+ cells in the stroma may
have a regulatory T-cell function, although activated ef-
fector human T cells can also express the FoxP3 marker.
Of the other inflammatory cell markers, expression of
CD11b (myeloid lineage marker) and CD25 (activated and
regulatory T cells) was also seen primarily in stromal tis-
sues, although the staining was generally quite weak and
variable, making it difficult to draw any conclusions. CD57
+ cells (a marker of natural killer cells) were rarely seen.
Lastly, we observed that all tumor samples from pa-
tients with CRC stained strongly with the group B
adenovirus receptors CD46 and DSG2 (data not shown).
Detection of enadenotucirev DNA in tumors
As an exploratory alternative to staining of enadenotu-
cirev hexons, qPCR was used to detect enadenotucirev
DNA after enadenotucirev administration to patients
(Fig. 4). Enadenotucirev DNA was detected after IV ad-
ministration of enadenotucirev in tumor samples from
11 of 12 patients (five CRC, one UCC, three RCC, two
NSCLC) and in two of five tumor samples after IT ad-
ministration. The difference in the rate of detection of
enadenotucirev DNA is probably due to the focal deliv-
ery by IT injection, which can lead to some tumor tissue
sections being taken from uninjected areas (see also
negative staining of some sections in Table 2).
Detection of enadenotucirev DNA in blood
Enadenotucirev DNA levels in blood samples following
IT injection in patients with CRC (cohort A) were below
the quantification limit of the qPCR assay (data not
shown). No enadenotucirev DNA was detected in blood
samples before the first IV infusion of enadenotucirev
on day 1 (cohorts B–E; Additional file 1: Figure S3) and
a cumulative effect of dosing on enadenotucirev DNA
level was not observed. The mean concentration of ena-
denotucirev in the blood was similar following IV
Table 3 Level of CD8 T-cell infiltration in tumor cell nests











aCD8 cell numbers were counted in a 1 mm2 area of tumor for two different
tissue blocks per patient, as described in Methods, with the average of the
two scores used here, with the exception of IT-204 and IV-201 where only one
CD8 stained section was available
Fig. 3 CD8 staining in samples from CRC patients (IT injection versus
IV infusion). 1. Image IT-301-B3-7 (top panel), tumor section from a
patient with CRC treated with enadenotucirev given by IT injection
(cohort A): brown CD8 staining (× 10 magnification) can be clearly
seen infiltrating the tumor cells. 2. Image IV-101-B4-7 (middle panel),
tumor section from a patient with CRC treated with enadenotucirev
given by IV infusion (cohort B): brown CD8 staining (× 10 magnification)
infiltrating the tumor cells can be clearly seen. 3. Image IT-302-B3-7
(bottom panel), tumor section from a patient with CRC treated with
enadenotucirev given by IT injection (cohort A): higher magnification
(× 40) showing closer detail of CD8-stained cells, which appear pleomorphic,
a hallmark of activated CD8+ T cells




















infusions on days 1, 3, and 5. Results were also similar in
samples from patients with different tumor types.
Patients with CRC had additional samples taken 6–8 h
after each IV infusion of enadenotucirev. On days 3 and
5, there was an approximately 80-fold decrease in virus
concentration over the 8 h following enadenotucirev in-
fusion, which is consistent with a circulating virus half-
life of approximately 20 min.
Detection of enadenotucirev DNA in urine, saliva, and
fecal samples (IT injection only)
Enadenotucirev DNA was not detected at significant
levels by qPCR in any urine or saliva samples at any
study time point (Additional file 2: Table S4). Enadeno-
tucirev DNA was detected in fecal samples from all pa-
tients who received enadenotucirev by IT injection and
was in the quantifiable range of the assay in two patients
(IT0201 and IT0204).
Enadenotucirev immunogenicity
The anti-enadenotucirev serum IgG titer before enadenotu-
cirev administration was undetectable or low (below 1/11
negative threshold) in all blood samples from all patients.
After administration of enadenotucirev by IT injection (co-
hort A), the mean anti-enadenotucirev titer remained low
at all time points (Additional file 1: Figure S4). After IV in-
fusion of enadenotucirev (cohorts B–E), the mean anti-
enadenotucirev titer was elevated and peaked at day 22 in
cohort B (1/79) and pre-surgery in cohorts C–E (cohort C,
1/149; cohort D, 1/174; cohort E, 1/167). Notably, antibody
levels remained low (< 1/100) in two-thirds of the patients
who received enadenotucirev by IV infusion. Antibody
titers remained detectable in all IV infusion cohorts until
study end. This study did not test whether these antibodies
were neutralizing.
Cytokine response (IV infusion only)
There was a trend for an increase in the concentrations
of IL-6, IL-10, and MCP-1 at 6–8 h after IV infusion of
enadenotucirev in the five patients with CRC in cohort
B (data not shown) but, generally, the concentration had
returned to the pre-infusion level at the next sample
(48 h after dosing). No other cytokine (IL-2, IL-4, IL-12,
IFNγ or TNF) showed any appreciable changes over
time during or after IV administration of enadenotucirev
(data not shown). Changes in cytokine responses were
not evaluated in other patients because of sampling
errors.
Discussion
This study was designed to assess viral delivery, viral ex-
pression, and inflammatory infiltrates within tumor tis-
sues when enadenotucirev is administered by either IT
injection or IV infusion to patients with CRC, and by IV
infusion to patients with several different epithelial
tumor types.
Enadenotucirev administration, whether by IT injec-
tion or IV infusion, was feasible and generally well toler-
ated. There was no evidence that enadenotucirev
resulted in any grade 3 or 4 AEs, SAEs, or AEs leading
to study discontinuation. Treatment-related AEs were
more frequent after IV infusion than after IT injection,
but were mild and were anticipated on the basis of pre-
liminary data from the EVOLVE study (manuscript in
Fig. 4 Enadenotucirev DNA detection in samples of epithelial tumors by qPCR (all cohorts). The exploratory qPCR analysis in patients with CRC
and other tumor types provides supporting evidence demonstrating that enadenotucirev can be delivered to several different carcinoma types
by IV infusion. Individual patient data are shown with corresponding identification in the key




















preparation) [35]. The lower number of events reported
after IT injection than IV infusion may be explained by
the lower systemic virus exposure following a lower total
administered dose (estimated 2–10% of the dose given
by IV infusion).
Short-term changes in cytokine levels are a specific
potential safety issue with oncolytic viruses. In previous
studies using high doses of systemically administered vi-
ruses, the cytokine profile has correlated closely with
signs of toxicity [36], such as the commonly observed
‘flu-like’ response, with cytokine levels peaking 6–48 h
after infusion and resolving 3–6 days later. Our results
demonstrate that systemic cytokine responses vary
greatly between patients. At 6–8 h after IV infusion of
enadenotucirev, there was a trend for an increase in the
levels of some inflammatory cytokines (IL-6, IL-10, and
MCP-1) but levels generally returned to pre-infusion
levels 48 h after dosing. We therefore conclude that IV
infusion of enadenotucirev at the doses administered in
this study is not associated with any of the serious cyto-
kine release-related events reported with other oncolytic
viral therapies.
Extensive IHC analysis of samples from patients with
CRC clearly showed effective delivery of enadenotucirev
to the tumor, with widespread nuclear hexon staining
(indicative of viral replication) and generally weak or
negative staining in non-tumor tissue. Successful deliv-
ery of virus to the tumor tissues was confirmed by qPCR
measurement of virus genomic DNA content. This se-
lective replication of enadenotucirev in tumor cells is
consistent with preclinical studies [7] and was achieved
irrespective of the enadenotucirev administration
method. IV infusion of enadenotucirev is therefore feas-
ible and may offer other advantages because it has the
potential to target disseminated tumor sites. Although
some clinical studies have reported occasional positive
staining for oncolytic virus delivery (in biopsies from 10
to 20% of patients) [37–40], to our knowledge, this is
the first clinical trial to clearly demonstrate consistent
delivery of an oncolytic virus to tumors with a favorable
safety profile following IV administration.
Further studies are required to determine the signifi-
cance of enadenotucirev hexon staining found in some
normal tissue and lymph nodes. Where staining did
occur in these cells, it was weak, there was no sign of
pathology, and the cells looked healthy. The proximity
of the normal samples to the excised tumor margin in
this study is unknown. It is therefore impossible to rule
out a direct influence of the tumor on these cells, such
as the effects of released cytokines, changes in vascular
permeability, or uptake of hexon proteins from viruses
released locally from lysed tumor cells. Furthermore,
some normal tissue close to a tumor can have precan-
cerous changes [41], which could predispose cells to
tumor development in the absence of morphologic
changes [42] and therefore increase the possibility of
their sensitization to enadenotucirev replication. The
specific cell type that stained positive for hexon in lymph
nodes was not established in this study.
Our study also provides indirect evidence supporting
the hypothesis that enadenotucirev may have stimulated
an immune response in the tumors of patients prior to
their resection. Large numbers of CD8+ cells were seen
in most tumor samples from the patients with CRC. In
CRC, CD8+ T-cell infiltration within tumor cell nests is
rare and is usually associated with MSI status [31]. All
CRC tumor samples in our study were microsatellite
stable; therefore, the high CD8+ cell numbers may repre-
sent an immune response to the enadenotucirev virus
infection rather than being induced by tumor hyper-
mutation in the context of MSI, although baseline sam-
ples were not analyzed for CD8+ cell infiltration. The
CD8 staining in these tumor samples had the same
localization pattern as that of PD-1 staining, suggesting
the possibility that many of these cells were activated
cytotoxic T cells (CTLs). A closer examination of their
cellular morphology revealed that many of these cells
were pleomorphic, consistent with a CTL activation
phenotype. Whether these putative CTLs could
recognize viral antigens from infected tumor cells and/
or immunologically processed tumor antigens from lysed
cells, or even whether they are pre-existing CTLs that
were inactivated within the tumor microenvironment, is
not known.
In contrast to CD8, CD4 staining was almost exclusively
restricted to stromal regions. Furthermore, the FoxP3
staining pattern aligned with that of CD4, perhaps reflect-
ing a CD4+/FoxP3+ Treg subset. Treg infiltration of tumor
sites is a well-documented feature of many forms of can-
cer, their presence contributing to a highly immunosup-
pressive microenvironment that facilitates tumor survival
[34, 43]. In our study, the localization of the Treg pheno-
typic marker FoxP3 to non-tumor stromal regions,
coupled with potentially activated CTL tumor infiltrates,
indirectly provides further support for the hypothesis that
enadenotucirev replication may be able to counterbalance
localized Treg-mediated immunosuppression.
Tumor cells present other barriers to an effective anti-
cancer immune response. For example, while activated
CD8+/PD-1+ CTLs can infiltrate tumors, they are fre-
quently thwarted in their anti-cancer role by tumor cell
expression of PD-1 ligand 1 (PD-L1), directly stimulated
by key CTL cytokines such as IFNγ, triggering a PD-1
dependent deactivation state known as ‘adaptive resist-
ance’ [33]. Staining for PD-L1 was variable and inconclu-
sive (data not shown). It is possible that the CD8+ cells
we observed in the tumor samples still face this obstacle
despite the physical exclusion of Treg cells. Combining




















the immune-stimulating properties of oncolytic viruses
with therapies designed to interfere with ligand recogni-
tion by PD-1 may be key to unlocking this deadlock
[44–46], a hypothesis that will be tested in a phase 1 trial
of enadenotucirev in combination with the PD-1 inhibi-
tor nivolumab (NCT02636036, SPICE).
Less extensive IHC was performed on samples from
patients with NSCLC, UCC, or RCC. Technical issues
made it difficult to draw firm conclusions about virus
delivery and activity in bladder, lung, and renal car-
cinomas using this analysis. The exploratory qPCR
analysis of enadenotucirev genomic DNA in tumor
tissue frozen at the time of resection did, however, in-
dicate virus delivery to these tumors after IV infusion
as well as to patients with CRC after administration
by both the IV and IT routes.
The virus particle kinetics of enadenotucirev (in whole
blood) administered by IV infusion suggest that repeated
infusion has a negligible impact on the clearance of the
virus. Enadenotucirev DNA was detectable following IV
infusion, but no significant levels of enadenotucirev DNA
were detectable in the bloodstream after IT injection. The
mean concentration of DNA was similar after each dose
administered by IV infusion, indicating that there was no
cumulative effect, and the kinetics appeared to be similar
in the different tumor types. Enadenotucirev DNA was de-
tected in all fecal samples, although it was not possible to
determine whether the genome was intact or partially de-
graded. This may reflect leakage of the virus from the site
of IT injection in the colon tumor.
An intrinsic advantage of enadenotucirev is its poten-
tially low immunogenicity, due to exclusive expression of
group B (Ad11p) viral coat proteins [26, 27]. Therefore, it
was unsurprising that all patients in the MOA study had
negligible levels of pre-existing antibodies to enadenotu-
cirev. Nevertheless, this is an important observation be-
cause enadenotucirev is unlikely to be neutralized by
patient antibodies immediately after administration. Anti-
enadenotucirev antibody titers were not raised in patients
following IT injection, whereas IV infusion appears to
elicit an antiviral immune response in some, but not all,
patients over time. However, with a single cycle of treat-
ment, as used in this study, antibodies do not appear to
play an important role in limiting delivery by IV infusion.
Conclusions
This study provides valuable early safety, targeting, kin-
etic, and immunological information to support the fu-
ture clinical development of enadenotucirev for systemic
administration by IV infusion, including the ongoing
combination study of enadenotucirev with the check-
point inhibitor nivolumab. We have shown that enade-
notucirev can gain access to and replicate within
different types of epithelial tumors, underlining its broad
therapeutic potential. This study also sheds light on the
pro-inflammatory nature of enadenotucirev.
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Additional file 1: Figure S1. Example of selective staining of tumor
tissue compared with normal tissue after IV infusion of enadenotucirev
(patient IV0302). Figure shows selective staining of tumor tissue (right-
hand side of margin) compared with normal epithelial cells (left-hand
side). Figure S2. Representative CD8, CD4, PD-1, and FoxP3 staining (Pa-
tient IV0101). This series of IHC stains illustrates a general finding amongst
patients treated with enadenotucirev: that PD-1 aligns with CD8, and
FoxP3 aligns with CD4. Figure S3. Virus kinetics in patients with CRC (co-
hort B) during treatment with enadenotucirev (EnAd) administered by IV
infusion. Each data point represents the mean value of all patients with
CRC treated with enadenotucirev (IV infusion) over the 5-day treatment
period (pre-treatment, immediately after infusion, and 6–8 h after infusion)
and a single pre-surgery sample. Limit of assay quantification (LOQ) ~ 2 × 105
vp. Similar data were observed for cohorts C–E (data not shown). Figure S4.
Detection of anti-enadenotucirev (EnAd) antibodies in patients following treat-
ment with enadenotucirev. All samples were diluted 1:100 prior to analysis (to
avoid serum inhibition). The titer shown is not corrected for this pre-dilution.
(DOCX 3462 kb)
Additional file 2: Table S1. Patient characteristics. Table S2. Nuclear
staining of enadenotucirev in non-tumor tissue samples from patients
with CRC (IT injection vs IV infusion). Table S3. Expression of the DNA
mismatch repair proteins MLH1 and MSH2 in tumor samples from
patients with CRC (IT injection and IV infusion). Table S4. Viral shedding
in patients with CRC treated with enadenotucirev by IT injection (cohort
A). (DOCX 80 kb)
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